Alzheimer’s: latest news - GoINPHARMA
Monday, 15 October 2018 - 12:13

Alzheimer’s

Celgene signs $150m agreement with Prothena to develop Alzheimer’s drug

Celgene has entered into an agreement with biotech Prothena in order to acquire the rights to three Alzheimer’s drug candidates based on three proteins identified by Prothena. Specifically, under the agreement, the companies will co-develop the drug candidates. Should these…

Hopes for Alzheimer’s therapy focus on Biogen (aducanumab)

Academia and investors were dejected as Pfizer last week announced it would end research for Alzheimer’s treatments. The few multinationals still working on Alzheimer’s – Eli Lilly, Biogen and Novartis – have recently said they are determined to keep funding…

Gloomy results from the research for an Alzheimer’s therapy

Alzheimer’s is a pathology affecting 44 million people globally, with an extremely high social cost, which – for example – is close to $249bn pa in the US. Only four approved therapies are currently available to ease the effects of…

Coffee consumption: more benefits than risks

A research investigating the safety of everyday coffee drinking has been published in the The British Medical Journal. The researchers have analyzed over 200 studies and have concluded that drinking two or three cups per day – that is 400mg…

Novartis, Amgen and Banner Alzheimer’s Institute, cooperation broadened

Novartis, Amgen and Banner Alzheimer’s Institute (BAI) have announced they have broadened their cooperation. Specifically, the companies have informed they will initiate the API (Alzheimer’s Prevention Initiative) Generation Study 2, designed to assess the CNP520 BACE1 inhibitor in preventing or…

Alzheimer’s: Ionis Initiates phase I/II trial for antisense drug

Ionis Pharmaceuticals has initiated its Phase I//IIa clinical trial designed to test IONIS-MAPTRx in patients with moderate Alzheimer’s disease. Having initiated this study, Ionis will receive a $10m milestone payment from Biogen. IONIS-MAPTRx is an antisense drug designed to selectively…

Alzheimer, significant results for Biogen’s aducanumab

Biogen today announced the results from an analysis of the long-term extension of its Phase Ib randomized, double-blind, placebo-controlled study of aducanumab, the investigational treatment for early Alzheimer’s disease. The new data include results from patients treated with aducanumab up…

Stress and Alzheimer’s: new data from AAI London Congress

The Alzheimer’s Association International Conference started today in London. Attendee’s interest was soon attracted by a study by the University of Wisconsin, showing a clear connection between traumas – such as job loss or sexual abuse – and the onset…

A setback for Alzheimer’s research

The recent halt to the Phase-III clinical trial assessing Verubecestat, a treatment developed by Merck & Co. for early Alzheimer’s, is a major setback for the amyloid hypothesis. A research branch developed in the last decade considers the development of…

Merck & Co. interrupts Alzheimer’s study for lack of efficacy

Merck & Co. announced yesterday after stock markets (Wall Street) closed that it has interrupted the EPOCH study evaluating verubecestat, a treatment for early Alzheimer’s disease. Indeed verubecestat – a BACE inhibitor – has virtually shown no benefit on a…

The pipelines of the groups working on Alzheimer’s treatments

Following the recently announced failure of Eli Lilly’s clinical trial, many analysts are drawing up new rankings of the pipelines of the most active groups in the Alzheimer’s treatment area. Germany-based biotech Probiodrug is focused on a research branch aimed…

Flickering light to treat Alzheimer’s

Flickering light could provide a non-pharmacological solution to treat Alzheimer’s. This is suggested by a study conducted by researchers at MIT, demonstrating that light—at a given frequency—can stimulate the removal of proteins harmful to the brain. The experiments, whose results…

Lilly/AstraZeneca deal for Alzheimer’s treatment

Eli Lilly and AstraZeneca announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42). The product is currently in Phase I development as a potential DMT (disease-modifying treatment) for Alzheimer’s disease. MEDI1814 binds selectively to Aβ42,…

FDA grants fast track for Eisai/Biogen’s BACE inhibitor

Eisai announced today that its product E2609, BACE (Beta-secretase Cleaving Enzyme) inhibitor, has received Fast Track designation. The product is currently in Phase III development, specifically in clinical trials designed in order to assess its efficacy for early Alzheimer’s disease….